Priscilla Locklear
Primary Care · Raeford, NCNPI 1982228748
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 153 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 23.2% — the pattern of someone who eats at a lot of different presentations.
Across 153 payments — averaging $15.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$547
- Lilly USA, LLC$294
- GSK$267
- AbbVie$205
- Pfizer$130
- Novartis$129
- plus $783 from 18 others
What the payments were for
- Food & beverage$2,354100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 40 | $547 |
| Lilly USA, LLC | 20 | $294 |
| GSK | 20 | $267 |
| AbbVie | 9 | $205 |
| Pfizer | 8 | $130 |
| Novartis | 8 | $129 |
| Amgen | 8 | $106 |
| Johnson & Johnson | 7 | $106 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $86 |
| Boehringer Ingelheim | 5 | $80 |
| Sanofi-aventis U.S. LLC | 5 | $71 |
| Ironwood Pharmaceuticals, Inc | 3 | $53 |
| AstraZeneca | 3 | $46 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $39 |
| Merck | 2 | $38 |
| Ultragenyx Pharmaceutical Inc. | 1 | $24 |
| Exact Sciences | 1 | $23 |
| Medtronic | 1 | $18 |
| Bayer | 1 | $17 |
| Eisai Inc. | 1 | $16 |
| Sunovion Pharmaceuticals Inc. | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $14 |
How this compares
$2,354 in reported general payments places this provider in the 80th percentile of 236 primary care providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 90 | $105,551 |
| MounjaroTirzepatide | 90 | $101,329 |
| JardianceEmpagliflozin | 74 | $60,944 |
| EliquisApixaban | 41 | $44,201 |
| RybelsusSemaglutide | 31 | $33,106 |
| FarxigaDapagliflozin Propanediol | 32 | $25,230 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $22,186 |
| TrulicityDulaglutide | 16 | $21,705 |
| LinzessLinaclotide | 15 | $21,271 |
| Nurtec OdtRimegepant Sulfate | 12 | $17,958 |
| TradjentaLinagliptin | 20 | $16,118 |
| Tresiba Flextouch U-100Insulin Degludec | 24 | $12,071 |
| JanumetSitagliptin Phos/Metformin Hcl | 11 | $11,232 |
| MyrbetriqMirabegron | 21 | $9,677 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $9,135 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $547 | $138,658121 claims |
| Lilly USA, LLCMounjaro, Trulicity | $294 | $123,034106 claims |
| Boehringer IngelheimJardiance, Tradjenta | $80 | $77,06294 claims |
| PfizerEliquis, Nurtec Odt | $130 | $62,15953 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $46 | $34,36547 claims |
| GSKTrelegy Ellipta | $267 | $22,18629 claims |
| AbbVieLinzess | $205 | $21,27115 claims |
| MerckJanumet | $38 | $11,23211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 236 primary care providers in North Carolina.
Other primary care in Raeford
- Cora KingRaeford$5K
- Jessica AllynRaleigh$21K
- Jennifer RogersWinston Salem$17K
- Elizabeth WaltersChapel Hill$14K
- Ragan JohnsonChapel Hill$13K
- Kirkland DickeyPine Hall$11K
- Kimberly WeaverHickory$9K
- Amanda StoneWilmington$9K
- Elizabeth WalshGreensboro$7K
- Mark HollingsworthWilmington$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.